about
Multiple myeloma in the very elderly patient: challenges and solutionsBendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.Time to redefine Myeloma.Serological normalisation as a surrogate marker for minimal residual disease negativity in multiple myelomaReal-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myelomaReducing infection-related morbidity and mortality in patients with myelomaCorrection: Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern eraRelative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysisClinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myelomaCarfilzomib therapy for relapsed myeloma: results of a UK multicentre experienceDPACE-based chemotherapy in the era of myeloma novel agents: a UK multicentre studyIn-house age-specific reference ranges for free light chains measured on the SPAPlus® analyserLong-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern eraLong term outcomes in monoclonal gammopathy of renal significanceResource implications of bortezomib therapy in a large UK cohort: An evaluation studyInfection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of carePathophysiology and management of monoclonal gammopathy of renal significanceUnplanned admissions for patients with myeloma in the UK: Low frequency but high costsTesting and management for monoclonal gammopathy of uncertain significance and myeloma patients presenting with osteoporosis and fragility fractures
P50
Q26752991-443C2FD8-650A-4CCC-A09B-C3848351D75CQ33418389-09F38C4B-846B-40F5-A981-975553AE1718Q48971392-95E2B710-BF09-4AD2-938B-B9AEDC41B053Q58593492-A1232714-BC21-4AC4-B150-6CF749E36D4BQ90821787-146DBF79-534B-495B-AC1F-9FEFE3AD2771Q91023573-AEF4976B-3DBC-4B54-9428-95D837ABFAE0Q91164810-BE148987-6A64-441F-9433-AF381DA662B2Q91222748-55A9816E-A9B4-410B-AE9E-835B1440F776Q91469768-5D329949-5B32-4442-8F66-854F6BC60C2DQ91625214-4D098C53-313B-4DB3-9BE8-C8CB8387E49DQ91732621-5F43B321-9E47-4953-8285-74B2BDB5D541Q92089337-196AD402-1D60-4E05-8F2D-D0F86ED3B596Q92121455-D7F77808-3D2F-4AB8-9024-935482D8DF9AQ92371898-535A9CEB-72B6-4755-A81A-67EA19956B11Q92479903-4F1E1AC3-1EB5-4333-AEFF-6F2A18F2BE7EQ92525386-3FA07A18-3203-43F6-AAFF-B14CEE575E48Q92600851-162BE1A0-C894-4AD9-8A95-669A1B93BD0AQ92930272-87E9DB91-B61E-4F66-850B-A5F69D01048EQ92934829-7ABC6A73-632D-4878-B4C6-36E1005F4679
P50
description
researcher (ORCID 0000-0003-3385-3707)
@en
wetenschapper
@nl
name
Karthik Ramasamy
@en
Karthik Ramasamy
@nl
type
label
Karthik Ramasamy
@en
Karthik Ramasamy
@nl
prefLabel
Karthik Ramasamy
@en
Karthik Ramasamy
@nl
P31
P496
0000-0003-3385-3707